Posterior Subtenon Injection of Triamcinolone (PSTT) for Macular Edema in Various Retinal Conditions
Spoorti Mundinamani1, Pavana Acharya2*, Kavitha Chikkanayakanahalli Venugopal3, Shruthi K4, Parvathy PS5
1 Post Graduate Student, Department of Ophthalmology, Hassan Institute of Medical Sciences, Hassan, Karnataka, India.
2 Assistant Professor, Department of Ophthalmology, Hassan Institute of Medical Sciences, Hassan, Karnataka, India.
3 Professor, Department of Ophthalmology, Hassan Institute of Medical Sciences, Hassan, Karnataka, India.
4 Post Graduate Student, Department of Ophthalmology, Hassan Institute of Medical Sciences, Hassan, Karnataka, India.
5 Department of Ophthalmology, Hassan Institute of Medical Sciences, Hassan, Karnataka, India.
*Corresponding Author
Dr. Pavana Acharya,
Assistant Professor, Department of Ophthalmology, Hassan Institute of Medical Sciences, Hassan-573201, India.
Tel: 9980005074
E-mail: pavanaacharya@yahoo.com
Received: June 11, 2020; Accepted: November 07, 2020; Published: November 16, 2020
Citation: Spoorti Mundinamani, Pavana Acharya, Kavitha Chikkanayakanahalli Venugopal, Shruthi K, Parvathy PS. Posterior Subtenon Injection of Triamcinolone (PSTT) for Macular Edema in Various Retinal Conditions. Int J Ophthalmol Eye Res. 2020;8(2):429-433. doi: dx.doi.org/10.19070/2332-290X-2000087
Copyright: Pavana Acharya© 2020. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
Importance: Cost effective way to resolve macular edema in few of the retinal conditions.
Background: To evaluate the effect on vision with Posterior Subtenon Triamcinolone acetonide injection for macular edema
in various retinal conditions.
Design: Prospective type of interventional study.
Participants: 60 eyes of 54 patients with macular edema secondary to various retinal conditions. Of 60 eyes,12 BRVO, 23
CSME, 10 CRVO, 3 vitritis, 12 neuroretinitis.
Methods: Pre and post injection (of Posterior subtenon Triamcinolone), BCVA and IOP were evaluated at 1st week, 1 and
3 months.
Results: The mean age- 57.87 yrs, 40 % were male and 60% were females. Pre injection Visual Acuity of <6/60 in 24, 6/60 –
6/24 in 21 and 6/18 - 6/6 in 15 patients. At least 2 line improvement in BCVA was noted in 28 eyes(46%) at the end of study
in which 11(39%) BRVO, 3(10%) CRVO, 8(33%)CSME, 4(14%) neuroretinitis and 2(7%)vitritis. 3 patients developed IOP of
>21mmHg controlled medically. No other complications were observed.
Conclusions: Posterior Subtenon Triamcinolone acetonide is a cost effective modality of treatment for macular edema associated
with retinal conditions with minimal complications.
2.Introduction
3.Material and Method
4.Results
5.Discussion
6.References
Keywords
Posterior Subtenon Triamcinolone Acetonide; Macular Edema; Vein Occlusions; Diabetic Macular Edema: Vitritis; Neuroretintis.
Introduction
Macular edema occurs secondary to various disorders like retinal
vein occlusions, diabetes, post cataract surgery, uveitis and neuroretinitis
which lead to gross diminution of vision. Various treatment
modalities have been tried to address the decreased vision
due to macular edema. The results have varying success rates.
About 5–15% of eyes with BRVO develop macular edema over
1 year and the majority of patients with CRVO have signs of
macular edema at presentation [1]. About 7 % of people with diabetes
may have DME [2]. Pseudophakic cystoid macular edema
has been reported to be between 1% and 30% [3]. In post fever
neuroretinitis, immunological reactions cause an increased vascular
permeability of the retinal vasculature leading to retinal edema
[4].
Resolution of macular edema can be long delayed. Cases that resolve
spontaneously over a long interval will have neuroretinal
or pigment epithelial scarring and atrophy. Hence, treatment of
macular edema is essential to improve the vision [1].
Various treatment modalities for macular edema are focal/grid
laser photocoagulation, Anti VEGF therapy (Pegaptinib sodium,
Ranibizumab, Bevacizumab) and corticosteroids (either as intravitreal
injection, intravitreal implants or subtenon injection).
Triamcinolone acetonide is a glucocorticoid which is used as periocular
injection in various ocular conditions like resistant anterior
uveitis, intermediate uveitis, posterior uveitis, age related macular
degeneration, macular edema due to vein occlusions (CRVO,
BRVO), macular edema secondary to diabetes, post cataract surgery
[5, 6]. Triamcinolone-acetonide in addition to its anti-inflammatory
effects, causes down-regulation of vascular endothelial
growth factor (VEGF) [7]. In retinal disorders, it is used as a depot
injection either through subtenon or intravitreally. Subtenon
injections are less invasive and has less complications when compared
to intravitreal injections [8]. The various complications of
intravitreal injection which can be bypassed by using subtenon
injections are vitreous haemorrhage, retinal detachment, vitreous
detachment, endophthalmitis, high intraocular pressure. Subtenon
corticosteroid is also cost effective compared to other modalities.
In this study, we evaluate the efficacy of posterior subtenon injection
of Triamcinolone acetonide injection in resolving macular
edema in retinal vein occlusions, diabetic maculopathy, post uveitis
and neuroretinitis.
Materials and Methods
A prospective interventional study was conducted in 60 eyes of
54 patients attending outpatient Department of Ophthalmology
at HIMS teaching Hospital ,Hassan , Karnataka in the study period
of December 2017 to September 2018.
Informed consent was taken from all patients included in the
study.
The patients are included in the study by applying the following
Inclusion and Exclusion criteria.
Inclusion criteria
Patient with macular edema secondary to vein occlusions, Diabetic
maculopathy, uveitis, neuroretinitis.
Exclusion criteria
Following patients will be excluded from the study-
• Traumatic macular edema.
• Patients with decreased vision due to cataract, corneal pathology, other retinal disorders.
• All patients with intraocular pressure more than 21 mmHg.
• Patients with prior laser,intra vitreal or subtenon injections.
Methodology
Patients fulfilling the inclusion criteria were recruited into the
study. Patients underwent BCVA, anterior segment evaluation,
dilatation and fundoscopy was done with indirect ophthalmoscopy
with 20D lens. IOP measurement was done with Perkin’s tonometer.
Posterior Subtenon Triamcinolone Acetonide injection
is given under local anaesthesia in operation theatre.
Under topical anaesthesia, injection of 0.5 ml of 20 mg of the
drug using a sharp tipped 25-gauge needle that was inserted in
the supratemporal quadrant of the eye, bevel of the needle facing
towards the globe, and needle advanced to the hub to obtain adequate
placement of the drug into the posterior sub tenon space.
Following injection, topical antibiotic was instilled and eye was
patched for 2 hours. Post procedure, patient was advised topical
antibiotic (Moxifloxacin) and topical NSAIDS for two weeks and
one month respectively.
Follow up
Patients were followed up at 1week, 1month, 3 months. During
follow up BCVA,IOP and dilated fundus examination was done.
Results
The study was conducted on 60 eyes of 54 patients with macular
edema secondary to various retinal conditions. Of 60 eyes,12
BRVO, 23 CSME, 10 CRVO, 3 vitritis, 12 neuroretinitis. The mean
age in BRVO group was 52 yrs, CRVO group was 63 years, DME
group was 55 years, Uveitis group was 39 years and Neuroretinitis
group was 35 years. All the groups showed female dominance.
Figure 3. No. of patients pre injection and post injection in BRVO group with their visual acuity represented in numbers as in table 1 , 11 out of 12 eyes show two line improvement.
Two line improvement in the Snellan’s visual acuity at the end of three months of follow up was considered as significant improvement.
Figure 4. No. of patients pre injection and post injection in CRVO group with their visual acuity represented in numbers as in table 1 , 3 out of 10 eyes show two line improvement.
Figure 5. No. of patients pre injection and post injection in DME group with their visual acuity represented in numbers as in table 1 , 13 out of 23 eyes show two line improvement.
Figure 6. No. of patients pre injection and post injection in neuroretinitis group with their visual acuity represented in numbers as in table 1 , 4 out of 12 eyes show two line improvement.
The vision at pre- injection and post injection:- Pre- injection vision in BRVO group - 2 had 6/60 , 7 had in the range of 6/60 – 6/24 , 3 had in the range of 6/18 - 6/6. Post injection, 1 had < 6/60, 2 had in the range of 6/60 - 6/24, 9 had in the range of 6/18 – 6/6.
Figure 7. No. of patients pre injection and post injection in vitritis group with their visual acuity represented in numbers as in table 1 , 2 out of 3 eyes show two line improvement.
Thus, two line improvement in Snellan’s visual acuity was seen in total of 28 eyes ( 46 %) of 60 eyes . Among them, 11 ( 39%) were BRVO , 3 ( 10%) were CRVO, 8 ( 33%) were DME , 2 ( 7%) were vitritis and 4 (14%) were neuroretinitis.
Raised IOP ( >21 mmHg) was noted in 4 eyes, one week after the injection which was controlled by the addition Timolol eye drops.
Discussion
Macular edema results from an increased vascular permeability
mediated at least in part by upregulation of VEGF. Triamcinolone
acetonide along with its anti inflammatory effect has been shown
to inhibit the expression of VEGF and thus reduce macular
edema in retinal vascular disease [8]. Early treatment of macular
edema may be better for visual improvement before longstanding
macular edema results in irreversible photoreceptor damage [9].
In our study, 3 out of 10 patients in CRVO group showed two
line improvement. Lin et al., in a prospective, non-comparative study treated 18 eyes of 18 patients of severe CME with recent
onset CRVO, with PSTT. They concluded that PSTT is effective
in reversing CME and improving VA in recent-onset CRVO. They
also recommended early treatment before long-standing macular
edema results in irreversible photoreceptor damage [9].
In our study, 11(90%) out of 12 BRVO patients had a two line
improvement post PSTT, similar results were seen in a study by
Nil et al. who evaluated 24 eyes with macular edema secondary
to RVO. All the eyes were treated with PSTT. 58.3% showed increased
BCVA with no major complications. They concluded that
PSTT was an effective therapeutic method to treat macular edema
associated with RVO [10].
In our study, two out of three patients with vitritis showed two
line improvement.In a study by Lanco Daflon et al ,nearly 80% of
the treated eyes with vitritis showed an improvement of at least 2
Snellen lines, and 20% of all eyes had an improvement of more
than 5 Snellen lines at long-term follow-up [11]. The same was
also studied by Helm et al., [12]
In our study, 8 (34%) out of 23 eyes with DME showed two line
improvement. PSTT in DME eyes was studied by Ozdek et al to
evaluate retro prospectively the clinical consequences of posterior
subtenon (PSTT) and intravitreal (IVT) triamcinolone acetonide
injections in diabetic macular edema (DME). They concluded that
both PSTT and IVT injections caused a significant increase in
visual acuity [13].
In our study, 4(14%) out of 12 eyes with neuroretinitis showed
two line improvement.The immunological nature of post fever
neuroretinitis and its favourable response to systemic steroids is
reported by sreelatha viswanath et al., [14].
Rise in intraocular pressure following posterior subtenon injection
and intra vitreal injection of triamcinolone acetonide is a
complication reported in various studies. However the incidence
in IOP rise is less in PST than in intra vitreal injection [15]. We
found no significant elevation in intraocular tension following the
procedure similar to the results of Bui Quocket et al., [16]
Conclusion
Posterior subtenon injection with triamcinolone acetonide can be
considered as a cost effective and safe alternate choice for treating
macular edema secondary to vein occlusions, diabetic macular
edema, parsplanitis, neuroretinitis without any risk of complications.
Ethical Considerations
Ethical clearance was obtained prior to the study from Institutional
Ethics Committee, HIMS, Hassan with reference no. IEC/
HIMS/014/30-05-2018. The study has been performed in accordance
with the ethical standards laid down in an appropriate
version of the Declaration of Helsinki.
References
- McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010 Jun 1; 117(6): 1113-23.
- Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and vision. 2015 Sep 30; 2(1): 17. PMID: 26605370.
- Grzybowski A, Sikorski BL, Ascaso FJ, Huerva V. Pseudophakic cystoid macular edema: update 2016. Clinical interventions in aging. 2016; 11: 1221-1229. PMID: 27672316.
- Purvin, Valerie MD, Sundaram, Seema MD, Kawasaki, Aki MD. Neuroretinitis: Review of the Literature and New Observations. J Neuroophthalmol 2011; 31(1): 58-68. PMID: 21317731.
- Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. British Journal of Ophthalmology. 2002 Feb 1; 86(2): 247-8.
- Ip MS, Gottlieb JL, Kahana A, Ingrid U Scott, Michael M Altaweel, Barbara A Blodi, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol. 2004; 122: 1131-1136. PMID: 15302652.
- Nauck M, Roth M, Tamm M, O Eickelberg, H Wieland, P Stulz, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is down regulated by corticosteroids. Am J Resp Cell Mol Biol. 1997; 16: 398-406. PMID: 9115750.
- Wakabayashi T, Okada AA, Morimura Y, Kojima E, Asano Y, Hirakata A, et al. Trans-tenon retrobulbar triamcinolone infusion for chronic macular edema in central and branch retinal vein occlusion. Retina. 2004 Dec 1; 24(6): 964-7.
- Lin JM, Chiu YT, HUNG T, Tsai YY. Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior sub-tenon triamcinolone acetonide. Retina. 2007; 27(2): 180-9. PMID: 17290200.
- Nil Rem, Mehmet, Cenk, Zeliha, Gursel Emin. Posterior Subtenon Triamcinolone Acetonide in the Treatment of Macular Edema Secondary to the Retinal Vein. Occlusion Journal of Retina-Vitreous. 2004; 12(3): 180–83.
- Marina Lafranco Dafflon, Van Tao Tran, Y Guex-Crosier, Carl P Herbort. Posterior sub-Tenon’s steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefe's Archive for Clinical and Experimental Ophthalmology. 1999; 237(4): 289–295. PMID: 10208261.
- Helm JH, Holland GN. The effects of posterior sub tenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995; 120: 55–64. PMID: 7611330.
- Özdek Ş, Bahçeci UA, Gürelik G, Hasanreisoğlu B. Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema. Journal of diabetes and its complications. 2006 Jul 1; 20(4): 246-51. PMID: 16798476.
- Srilatha Vishwanath, Kalpana Badami, KS Sriprakash, BL Sujatha, SD Shashidhar, YD Shilpa. Post-fever retinitis: a single center experience from south India. Int Ophthalmol. 2014; 34: 851–857. PMID: 24362635.
- Iwao K, Inatani M, Kawaji T, Koga T, Mawatari Y, Tanihara H. Frequency and risk factors for intraocular pressure elevation after posterior sub-Tenon capsule triamcinolone acetonide injection. Journal of Glaucoma. 2007; 16(2): 251-6. PMID: 17473740.
- Bui Quoc E, Bodaghi B, Adam R, Burtin T, Cassoux N, Dreifuss S, et al. Intraocular pressure elevation after subtenon injection of triamcinolone acetonide during uveitis. J Fr Ophtalmol 2002; 25(10): 1048-56. PMID: 12527830.